Association of Circulating IGFBP1 Level with the Severity of Coronary Artery Lesions in Patients with Unstable Angina

Zheng, Wei; Lai, Yayu; Peng, Jin; Gu, Wenzhu; Zhou, Qi; Wu, Xiaojing

doi:10.1155/2017/1917291

Cited by 13 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When combined with HDL values, the sensitivity was 0.82. The phosphorylation status was not determined (Zheng et al 2017). Similarly, high IGFBP1 predicted increased risk of mortality in elderly women with the hazard ratio of 3/1 when compared to low IGFBP1 values (Maggio et al 2013).…”

Section: Journal Of Molecular Endocrinologymentioning

confidence: 99%

40 YEARS OF IGF1: Role of IGF-binding proteins in regulating IGF responses to changes in metabolism

Clemmons

2018

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

The IGF-binding protein family contains six members that share significant structural homology. Their principal function is to regulate the actions of IGF1 and IGF2. These proteins are present in plasma and extracellular fluids and regulate access of both IGF1 and II to the type I IGF receptor. Additionally, they have functions that are independent of their ability to bind IGFs. Each protein is regulated independently of IGF1 and IGF2, and this provides an important mechanism by which other hormones and physiologic variables can regulate IGF actions indirectly. Several members of the family are sensitive to changes in intermediary metabolism. Specifically the presence of obesity/insulin resistance can significantly alter the expression of these proteins. Similarly changes in nutrition or catabolism can alter their synthesis and degradation. Multiple hormones such as glucocorticoids, androgens, estrogen and insulin regulate IGFBP synthesis and bioavailability. In addition to their ability to regulate IGF access to receptors these proteins can bind to distinct cell surface proteins or proteins in extracellular matrix and several cellular functions are influenced by these interactions. IGFBPs can be transported intracellularly and interact with nuclear proteins to alter cellular physiology. In pathophysiologic states, there is significant dysregulation between the changes in IGFBP synthesis and bioavailability and changes in IGF1 and IGF2. These discordant changes can lead to marked alterations in IGF action. Although binding protein physiology and pathophysiology are complex, experimental results have provided an important avenue for understanding how IGF actions are regulated in a variety of physiologic and pathophysiologic conditions.

show abstract

Section: Journal Of Molecular Endocrinologymentioning

confidence: 99%

40 YEARS OF IGF1: Role of IGF-binding proteins in regulating IGF responses to changes in metabolism

Clemmons

2018

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

show abstract

“…One new finding emerging from our study utilizing a modern metabolomics approach is that there was an inverse correlation between the level of phIGFBP-1 and several HDL-related particles, which were independent of the serum level of insulin and prepregnancy BMI. In previous studies in non-pregnant study groups, the level of IGFBP-1 has been found to correlate with traditionally measured serum total HDL cholesterol in ischaemic heart disease, type 2 diabetic patients and healthy subjects [ 25 , 26 , 27 ] and in patients with unstable angina [ 28 ]. The inverse relationship between phIGFBP-1 and HDL–particles in our study may be related to the physiological alterations in lipid metabolism associated with pregnancy: typically an increase in the amounts of lipids, particularly in triglycerides and total cholesterol has been reported over the course of pregnancy [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Early pregnancy serum IGFBP-1 relates to lipid profile in overweight and obese women

Mokkala

Juhila²,

Houttu

et al. 2020

Heliyon

View full text Add to dashboard Cite

Lower level of insulin-like growth factor-binding protein (IGFBP-1) has been observed in insulin resistance, while higher level of matrix metalloproteinase-8 (MMP-8) has been linked to obesity. The aim here was to study in overweight and obese women, typically manifesting with insulin resistance, whether IGFBP-1 and MMP-8 are related to and reflect systemic low-grade inflammation, metabolism and diet. Fasting serum from overweight and obese pregnant women (n = 100) in early pregnancy were analysed for IGFBP-1, phosphorylated IGFBP-1 (phIGFBP-1) and MMP-8. High-sensitivity CRP and GlycA were used as markers for low grade inflammation. GlycA and lipids were quantified using NMR. IGFBP-1 associated negatively with GlycA, evidenced by higher concentrations in the lowest quartile (median 1.53 (IQR 1.45–1.72)) compared to the highest (1.46 (1.39–1.55)) (P = 0.03). Several lipid metabolites, particularly HDL-cholesterol, correlated inversely with phIGFBP-1 (FDR<0.1). Nutritional status and diet contributed to the levels of IGFBP-1, demonstrated as an inverse correlation with maternal weight (Spearman r = -0.205, P = 0.04) and dietary intake of vitamin A (r = -0.253, P = 0.014) and a direct correlation with dietary intake of polyunsaturated fatty acids (Spearman r = 0.222, P = 0.03). MMP-8 correlated inversely with pyridoxine (r = -0.321, P = 0.002) and potassium (r = -0.220, P = 0.033). Maternal serum IGFBP-1 may contribute to maternal lipid metabolism in overweight and obese women during early pregnancy. These findings may be of importance in identification of metabolic disturbances preceding the adverse metabolic outcomes in pregnancy.

show abstract

“…Interestingly, higher IGFBP-1 concentrations were informative for mortality in subjects with no history of heart failure after a follow-up of 8 years. Serum IGFBP-1 concentrations were also significantly increased in patients with critical CAD when compared to patients with less severe CAD ( 22 ). In combination with HDL cholesterol, IGFBP-1 serum concentrations were more sensitive and specific for the prediction of CAD ( 22 ).…”

Section: Igfbp-1mentioning

confidence: 98%

“…Serum IGFBP-1 concentrations were also significantly increased in patients with critical CAD when compared to patients with less severe CAD ( 22 ). In combination with HDL cholesterol, IGFBP-1 serum concentrations were more sensitive and specific for the prediction of CAD ( 22 ). Lower IGFBP-1 and IGF-I serum concentrations were associated with an increased risk of IHD later in life or with higher cardiovascular disease mortality in men and women at an age between 51 and 98 years ( 28 ).…”

Section: Igfbp-1mentioning

confidence: 98%

“…These correlations have been confirmed by several consecutive studies ( 18 , 19 ). However, in patients with heart failure, IGFBP-1 levels have been shown to be increased, although not associated with outcome ( 21 ), and in 112 patients with unstable angina, IGFBP-1 levels correlated with ACS disease severity and are higher in patients with multivessel disease than those with single-vessel ( 22 ). High circulating IGFBP-1 was also significantly associated with morbidity and cardiovascular mortality in a study including more than 500 diabetic patients with AMI ( 23 ).…”

Section: Igfbp-1mentioning

confidence: 99%

See 1 more Smart Citation

Current IGFBP-Related Biomarker Research in Cardiovascular Disease—We Need More Structural and Functional Information in Clinical Studies

2018

View full text Add to dashboard Cite

Cardiovascular diseases are the leading cause of death around the world and the insulin-like growth factor (IGF)-system has multiple functions for the pathological conditions of atherosclerosis. IGF binding proteins (IGFBPs) are widely investigated as biomarkers for pathological disorders, including those of the heart. At the tissue level, IGFBP-1 to -6 decrease bioactivity of IGF-I and -II due to their high affinity IGF-binding sites. By contrast, in the circulation, the IGFBPs increase biological half-life of the IGFs and may therefore be regarded as positive regulators of IGF-effects. The IGFBPs may also exert IGF-independent functions inside or outside the cell. Importantly, the circulating IGFBP-concentrations are regulated by trophic, metabolic, and reproductive hormones. In a multitude of studies of healthy subjects and patients with coronary heart diseases, various significant associations between circulating IGFBP-levels and defined parameters have been reported. However, the complex hormonal and conditional control of IGFBPs may explain the lack of clear associations between IGFBPs and parameters of cardiac failure in broader studies including larger populations. Furthermore, the IGFBPs are subject to posttranslational modifications and proteolytic degradation by proteases, upon which the IGFs are released. In this review, we emphasize that, with the exception of IGFBP-4 and in sharp contrast to the preclinical studies, virtually all clinical studies do not have structural or functional information on their biomarker. The use of analytical systems with no discriminatory potential toward intact vs. fragmented IGFBPs represents a major issue in IGFBP-related biomarker research and an important focus point for the future. Overall, measurements of selected IGFBPs or more complex IGFBP-signatures of the family of IGFBPs have potential to identify pathophysiological alterations in the heart or patients with high cardiovascular risk, particularly if defined cohorts are to be assessed. However, a more thorough understanding of the dynamic IGF-IGFBP system as well as its proteases and protease inhibitors in both normal physiology and in cardiovascular diseases is necessary.

show abstract

Association of Circulating IGFBP1 Level with the Severity of Coronary Artery Lesions in Patients with Unstable Angina

Cited by 13 publications

References 24 publications

40 YEARS OF IGF1: Role of IGF-binding proteins in regulating IGF responses to changes in metabolism

40 YEARS OF IGF1: Role of IGF-binding proteins in regulating IGF responses to changes in metabolism

Early pregnancy serum IGFBP-1 relates to lipid profile in overweight and obese women

Current IGFBP-Related Biomarker Research in Cardiovascular Disease—We Need More Structural and Functional Information in Clinical Studies

Contact Info

Product

Resources

About